Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
(FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (Q3)May 31, 2024 | (Q2)Feb 29, 2024 | (Q1)Nov 30, 2023 | (FY)Aug 31, 2023 | (Q4)Aug 31, 2023 | (Q3)May 31, 2023 | (FY)Aug 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.22%3.78B | 1.65%958.24M | -2.47%943.13M | 958.25M | 919.71M | 4.11%3.77B | 942.66M | 966.96M | 3.62B |
Cost of revenue | 2.30%2.83B | 2.12%731.36M | -1.05%686.61M | 719.22M | 691.11M | 4.24%2.76B | 716.21M | 693.87M | 2.65B |
Gross profit | -5.50%951.02M | 0.19%226.88M | -6.07%256.51M | 239.02M | 228.6M | 3.74%1.01B | 226.45M | 273.09M | 970.11M |
Operating expense | 0.98%942.83M | -3.60%227.06M | 3.30%276.44M | 226.75M | 212.58M | 6.41%933.71M | 235.53M | 267.61M | 877.47M |
Operating profit | -88.73%8.19M | 98.06%-176K | -463.77%-19.93M | 12.28M | 16.02M | -21.59%72.64M | -9.08M | 5.48M | 92.65M |
Net non-operating interest income (expenses) | -35.27%-6.72M | 23.05%2.72M | -41.75%-6.43M | -1.51M | -1.5M | 8.41%-4.97M | 2.21M | -4.54M | -5.42M |
Non-operating interest income | 194.74%112K | 727.27%91K | -28.57%5K | --11K | --5K | -20.83%38K | --11K | --7K | --48K |
Non-operating interest expense | 36.48%6.83M | 109.48%2.39M | 17.89%1.42M | --1.52M | --1.51M | -8.52%5.01M | --1.14M | --1.2M | --5.47M |
Net investment income | |||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | |||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 21.7M | -566K | 0 | 0 | 22.26M | 0 | 0 | 0 | |
Income from associates and other participating interests | |||||||||
Special income (charges) | 0 | -100.10%-287K | 288.55M | ||||||
Less:Other special charges | ---- | ---- | ---- | ---- | ---- | 100.10%287K | ---- | ---- | ---288.55M |
Other non-operating income (expenses) | 177.71%9.22M | 66.43%-4.05M | 773.48%15.21M | 435K | -2.38M | -1,683.18%-11.86M | -12.07M | -2.26M | 749K |
Income before tax | -41.68%32.38M | 89.23%-2.07M | -748.40%-11.15M | 11.38M | 34.22M | -85.25%55.53M | -19.23M | -1.31M | 376.52M |
Income tax | -26.41%12.81M | 115.58%1.42M | -511.54%-5.83M | 5.72M | 11.49M | -58.33%17.41M | -9.13M | -953K | 41.77M |
Net income | -48.65%19.57M | 65.39%-3.49M | -1,373.68%-5.32M | 5.66M | 22.73M | -88.61%38.12M | -10.09M | -361K | 334.75M |
Net income continuous operations | -48.65%19.57M | 65.39%-3.49M | -1,373.68%-5.32M | --5.66M | --22.73M | -88.61%38.12M | ---10.09M | ---361K | --334.75M |
Noncontrolling interests | |||||||||
Net income attributable to the company | -48.65%19.57M | 65.40%-3.49M | -1,369.61%-5.32M | 5.66M | 22.73M | -88.61%38.12M | -10.09M | -362K | 334.75M |
Preferred stock dividends | |||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -48.65%19.57M | 65.40%-3.49M | -1,369.61%-5.32M | 5.66M | 22.73M | -88.61%38.12M | -10.09M | -362K | 334.75M |
Gross dividend payment | |||||||||
Basic earnings per share | -48.68%4.66 | 65.41%-0.83 | -1,373.49%-1.27 | 1.35 | 5.41 | -88.61%9.08 | -2.3993 | -0.0862 | 79.7019 |
Diluted earnings per share | -48.72%4.6 | 65.46%-0.83 | -1,373.49%-1.27 | 1.3471 | 5.41 | -88.75%8.97 | -2.4033 | -0.0862 | 79.7019 |
Dividend per share | -50.00%1.5 | -50.00%1.5 | 0 | 0 | 0 | 3 | 3 | ||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |